Advicenne Launches IPO With Kidney Drug Close To Filing

 
• By Kevin Grogan

Looking to raise up to €39.7m through a stock market listing, French firm Advicenne has been developing ADV7103, which could soon become the first drug to be approved for distal renal tubular acidosis.

Paper planes
Ready for launch: Advicenne hopes IPO will raise nearly €40m • Source: Shutterstock

More from Financing

More from Business